BIOS Health GTM brain

BIOS Health develops neural interfaces and AI analysis for pharmaceutical, medical technology and research partners exploring precision therapies.

category

Neural data and bioelectronic medicine

market profile

  • text: Bioelectronic and drug developers seek to understand neural signals and use biomarkers to guide research and therapy development.
  • text: Neural-cardiac therapy development involves collaboration across pharmaceutical R&D, academia and technology organizations.

personas

  • title: Pharma neuroscience or cardiovascular R&D leader
    pains:
    • Drug development lacks direct, timely insight into nervous-system response
    • Identifying biomarkers for targeted chronic disease therapies is difficult
  • title: Bioelectronic medical device R&D director
    pains:
    • Must interpret complex neural signals and tailor stimulation
    • Needs evidence and collaborators to translate early research into a viable therapy
  • title: Translational neuroscience principal investigator
    pains:
    • Neural recording and analysis require specialized hardware and computational skills
    • Connecting neural signals to physiological outcomes across studies is challenging

icp

  • text: Pharmaceutical and biotechnology R&D organizations pursuing cardiovascular, autonomic or other chronic disease therapies.
  • text: Medical device developers and academic research centers with neural interface or bioelectronic therapy programs; no firm-size threshold disclosed.

message pillars

  • text: Read and analyze nervous-system signals in real time.
  • text: Use neural biomarkers to inform new treatments.
  • text: Personalize neural therapies with recordings and AI.
  • text: Develop therapies through long-term partnerships.

objections

  • objection: Is this clinically validated for our indication?
    response: Request indication-specific study evidence, intended use and current regulatory status; do not assume a marketed clinical treatment.
  • objection: Can neural data fit our existing development program?
    response: Define a joint feasibility study with sample collection, signal quality and biomarker endpoints before committing to a larger collaboration.
  • objection: How are commercial rights and timelines structured?
    response: Scope data ownership, intellectual property, milestones and commercialization responsibilities during partnership negotiations.

competitors

  • name: Galvani Bioelectronics
    why: Adjacent bioelectronic medicine developer targeting disease through neural modulation.
  • name: SetPoint Medical
    why: Develops bioelectronic therapies for chronic disease, competing for development attention and partners.
  • name: CorTec
    why: Neural interface and bioelectronic technology provider in the same broad market.

keywords

  • neural biomarkers drug discovery
  • bioelectronic medicine development
  • autonomic nervous system biomarkers
  • neural interface AI
  • closed loop neuromodulation
  • neural dosing platform
  • cardiovascular neural therapy

voice

  • Visionary and science-led
  • Precision medicine focused
  • Collaborative

signals

  • text: A pharma company launches a bioelectronic or autonomic biomarker program and seeks neural data partners.
  • text: A device developer needs neural recordings and analysis for adaptive therapy research.

stack

  • NVIDIA GPUs

pricing

model: unknown

motion

sales_led

channels

  • research partnerships
  • company blog
  • industry press

confidence

medium

Founders

  • name: Oliver Armitage
    title: Founder
    role: Founder
  • name: Emil Hewage
    title: Founder/Director
    role: Founder

Back to YC companies